Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Has Consensus Price Target of $18.25

Posted by Brian Himes on Nov 3rd, 2026

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $18.25.

Several analysts have issued reports on UNCY shares. Benchmark restated a “speculative buy” rating and issued a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. B. Riley Financial reaffirmed a “buy” rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Finally, Guggenheim reaffirmed a “buy” rating and set a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th.

Check Out Our Latest Analysis on UNCY

Unicycive Therapeutics Stock Performance

Unicycive Therapeutics stock opened at $3.49 on Tuesday. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74. The firm’s 50-day simple moving average is $4.50 and its 200 day simple moving average is $6.07. The stock has a market cap of $97.20 million, a PE ratio of -1.99 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.41. As a group, analysts predict that Unicycive Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics in the 1st quarter valued at approximately $940,000. Seven Fleet Capital Management LP boosted its holdings in shares of Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after acquiring an additional 47,700 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Unicycive Therapeutics in the second quarter valued at $248,000. Bank of America Corp DE grew its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares in the last quarter. Finally, Chicago Partners Investment Group LLC raised its stake in shares of Unicycive Therapeutics by 26.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after purchasing an additional 5,556 shares during the period. Institutional investors own 40.42% of the company’s stock.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.